Investigating The Antifungal Activity of Atorvastatin Compared with Nystatin on Oral Candidiasis before and during Head and Neck Radiotherapy

Atorvastatin Vs. Nystatin for Oral Candidiasis in Radiotherapy

Authors

  • Zahra Golestannejad Department of Oral and Maxillofacial Medicine, Dental Research Center, Dental Research Institute, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran
  • Faezeh Khozeimeh Department of Oral and Maxillofacial Medicine, Dental Research Center, Dental Research Institute, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran
  • Sara Taheri School of Dentistry, Dental Research Center, Dental Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  • Soha Feyzi Department of Stomatology, Xi'an Jiaotong University, Xi'an, China
  • Fatemeh Abbasi Department of Oral Medicine, Dental Research Center, Dental Research Institute, Faculty of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran
  • Zahra Saberi Department of Oral and Maxillofacial Medicine, Dental Research Center, Dental Research Institute, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran
  • Elham Faghihian Department of Oral and Maxillofacial Medicine, Dental Research Center, Dental Research Institute, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran
  • Parvin Dehghan Department of Mycology and Parasitology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Faezeh Tadayon Department of Dentistry, Dental Students Research Committee, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran
  • Mahnaz Kheirkhah Department of Mycology and Parasitology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Zeinab Nourmohammadi Najafabadi Dentistry Department, Isfahan University of Medical Science, Isfahan, Iran
  • Zahra Ataie Dental Research Center, Dental Research Institute, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran

DOI:

https://doi.org/10.31661/gmj.v13iSP1.3717

Keywords:

Oral Candidiasis; Antifungal Activity; Nystatin; Atorvastatin; Radiotherapy; Head and Neck Tumor

Abstract

Background: Radiotherapy plays an imperative role in the control of head and neck malignancies; however, it can damage oral tissues and salivary glands. These damages can alter oral Candida species and lead to the expansion of oral candidiasis resistant to common antifungal mediators, including nystatin. Atorvastatin, a serum cholesterol-lowering drug, has potential antifungal activities by inhibiting the synthesis of ergosterol in the fungal wall and disrupting mitochondrial function. This study aimed to determine and equivalence the antifungal activities of nystatin and atorvastatin on Candida species isolated from the mouths of patients undergoing head and neck radiotherapy before and during radiotherapy. Materials and Methods: This was an in vitro laboratory research conducted on samples isolated from patients experiencing head and neck radiotherapy, before and during radiotherapy. After determining the Candida species using the PCR-RFLP method, the antifungal activity of both nystatin and atorvastatin was evaluated by microdilution method according to CLSI standards, and the minimum inhibitory concentration (MIC) and minimum lethal concentration (MFC) of each drug were measured. Results: According to our findings, atorvastatin had less activity in inhibiting and killing different Candida species compared to nystatin before and during radiotherapy. Before radiotherapy, the MIC and MFC indices for nystatin against Candida albicans (P <0.001), tropical (P<0.001) and glabrata (P<0.001) were significantly lower than these three indices (P-value <0.001) for atorvastatin. The results of these indices in the second week of radiotherapy were similar to the results before radiotherapy. The MIC and MFC results for Candida albicans and tropicalis were obtained with a P-value <0.001 and for glabrata with a P-value = 0.002. Conclusion: The discoveries of this study indicate that atorvastatin exhibits lower antifungal activity compared to nystatin in treating oral candidiasis among patients receiving head and neck radiotherapy, both before and during the treatment.

References

Vissink A, Jansma J, Spijkervet F, Burlage F, Coppes R. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med. 2003;14(3):199-212.

https://doi.org/10.1177/154411130301400305

PMid:12799323

Golestannejad Z, Khozeimeh F, Dehghan P, Najafizadeh N, Faghihian E, Kheirkhah M, et al. Comparison of the antifungal effect of voriconazole and fluconazole on oral candidiasis before and during radiotherapy. DRJ. 2022;19:99.

https://doi.org/10.4103/1735-3327.361359

PMid:36605149 PMCid:PMC9807927

Leung WK, Dassanayake RS, Yau JY, Jin LJ, Yam WC, Samaranayake LP. Oral colonization, phenotypic, and genotypic profiles of Candida species in irradiated, dentate, xerostomic nasopharyngeal carcinoma survivors. J Clin Microbiol. 2000;38(6):2219-26.

https://doi.org/10.1128/JCM.38.6.2219-2226.2000

PMid:10834980 PMCid:PMC86768

Schelenz S, Abdallah S, Gray G, Stubbings H, Gow I, Baker P, et al. Epidemiology of oral yeast colonization and infection in patients with hematological malignancies, head neck and solid tumors. J Oral Pathol Med. 2011;40(1):83-9.

https://doi.org/10.1111/j.1600-0714.2010.00937.x

PMid:20923440

Mañas A, Cerezo L, de la Torre A, García M, Alburquerque H, Ludeña B, et al. Epidemiology and prevalence of oropharyngeal candidiasis in Spanish patients with head and neck tumors undergoing radiotherapy treatment alone or in combination with chemotherapy. Clin Transl Oncol. 2012;14(10):740-6.

https://doi.org/10.1007/s12094-012-0861-8

PMid:22960994

Ramla S, Sharma V, Patel M. Influence of cancer treatment on the Candida albicans isolated from the oral cavities of cancer patients. Supportive care in cancer: Support Care Cancer. 2016;24(6):2429-36.

https://doi.org/10.1007/s00520-015-3035-8

PMid:26638003

Jham BC, França EC, Oliveira RR, Santos VR, Kowalski LP, da Silva Freire AR. Candida oral colonization and infection in Brazilian patients undergoing head and neck radiotherapy: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(3):355-8.

https://doi.org/10.1016/j.tripleo.2006.02.005

PMid:17321446

Suryawanshi H, Ganvir SM, Hazarey VK, Wanjare VS. Oropharyngeal candidosis relative frequency in radiotherapy patient for head and neck cancer. JOMFP. 2012;16(1):31.

https://doi.org/10.4103/0973-029X.92970

PMid:22438640 PMCid:PMC3303519

Paula CR, Sampaio MCC, Birman EG, Siqueira AM. Oral yeasts in patients with cancer of the mouth, before and during radiotherapy. Mycopathologia. 1990;112(2):119-24.

https://doi.org/10.1007/BF00436507

PMid:2293033

Torres SR, Peixoto CB, Caldas DM, Silva EB, Akiti T, Nucci M, et al. Relationship between salivary flow rates and Candida counts in subjects with xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93(2):149-54.

https://doi.org/10.1067/moe.2002.119738

PMid:11862202

Epstein JB, Freilich MM, Le ND. Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol. 1993;76(2):169-74.

https://doi.org/10.1016/0030-4220(93)90199-E

PMid:8361726

Redding SW. The role of yeasts other than Candida albicans in oropharyngeal candidiasis. Curr Opin Infect Dis. 2001;14(6):673-7.

https://doi.org/10.1097/00001432-200112000-00002

PMid:11964883

Prasad R, Shah AH, Rawal MK. Antifungals: Mechanism of Action and Drug Resistance. Adv Exp Med Biol. 2016;892:327-49.

https://doi.org/10.1007/978-3-319-25304-6_14

PMid:26721281

Rajni E, Chaudhary P, Garg VK, Sharma R, Malik M. A complete clinico-epidemiological and microbiological profile of candidemia cases in a tertiary-care hospital in Western India. ASHE. 2022;2(1):e37.

https://doi.org/10.1017/ash.2021.235

PMid:36310808 PMCid:PMC9614779

Westermeyer C, Macreadie IG. Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata. FEMS Yeast Res. 2007;7(3):436-41.

https://doi.org/10.1111/j.1567-1364.2006.00194.x

PMid:17257373

Nyilasi I, Kocsube S, Pesti M, Lukács G, Papp T, Vágvölgyi C. In vitro interactions between primycin and different statins in their effects against some clinically important. fungi J Med Microbiol. 2010;59(2):200-5.

https://doi.org/10.1099/jmm.0.013946-0

PMid:19875509

Westermeyer C, Macreadie IG. Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata. FEMS Yeast Res. 2007;7(3):436-41.

https://doi.org/10.1111/j.1567-1364.2006.00194.x

PMid:17257373

Katiraee F, Teifoori F, Soltani M. Emergence of azole-resistant Candida species in AIDS patients with oropharyngeal candidiasis in Iran. Curr Med Mycol. 2015;1(3):11-6.

https://doi.org/10.18869/acadpub.cmm.1.3.11

PMid:28680991 PMCid:PMC5490324

Esfahani AN, Golestannejad Z, Khozeimeh F, Dehghan P, Maheronnaghsh M, Zarei Z. Antifungal effect of Atorvastatin against Candida species in comparison to Fluconazole and Nystatin. Med Pharm Rep. 2019;92(4):368-73.

https://doi.org/10.15386/mpr-1209

PMid:31750437 PMCid:PMC6853048

de Oliveira Neto AS, Souza ILA, Amorim MES, de Freitas Souza T, Rocha VN, do Couto RO, et al. Antifungal efficacy of atorvastatin-containing emulgel in the treatment of oral and vulvovaginal candidiasis. Med Mycol. 2021;59(5):476-85.

https://doi.org/10.1093/mmy/myaa071

PMid:32823281

Lima WG, Alves-Nascimento LA, Andrade JT, Vieira L, de Azambuja Ribeiro RIM, Thomé RG, et al. Are the Statins promising antifungal agents against invasive candidiasis? BIOMED PHARMACOTHER. 2019;111:270-81.

https://doi.org/10.1016/j.biopha.2018.12.076

PMid:30590315

Nyilasi I. Effect of different statins on the antifungal activity of polyene antimycotics. Acta Biol Szeged. 2010;54(1):33-6.

Davis D. Adaptation to environmental pH in Candida albicans and its relation to pathogenesis. Curr Genet. 2003;44(1):1-7.

https://doi.org/10.1007/s00294-003-0415-2

PMid:12819929

Brilhante RSN, Caetano EP, Oliveira JSd, Castelo-Branco DdSC, Souza ERY, Alencar LPd, et al. Simvastatin inhibits planktonic cells and biofilms ofCandida and Cryptococcusspecies. BJID. 2015;19(5):459-65.

https://doi.org/10.1016/j.bjid.2015.06.001

PMid:26119850 PMCid:PMC9427464

Ting M, Whitaker EJ, Albandar JM. Systematic review of the in vitro effects of statins on oral and perioral microorganisms. Eur J Oral Sci. 2016;124(1):4-10.

https://doi.org/10.1111/eos.12239

PMid:26718458

Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis. 2007;44(8):1089-90.

https://doi.org/10.1086/512817

PMid:17366455

Sun Y, Cao C, Jia W, Tao L, Guan G, Huang G. pH regulates white-opaque switching and sexual mating in Candida albicans. Eukaryot Cell. 2015;14(11):1127-34.

https://doi.org/10.1128/EC.00123-15

PMid:26342021 PMCid:PMC4621312

Bensadoun RJ, Patton LL, Lalla RV, Epstein JB. Oropharyngeal candidiasis in head and neck cancer patients treated with radiation: update 2011. Supportive care in cancer: Support Care Cancer. 2011;19(6):737-44.

https://doi.org/10.1007/s00520-011-1154-4

PMid:21479787

Karbach J, Walter C, Al-Nawas B. Evaluation of saliva flow rates, Candida colonization and susceptibility of Candida strains after head and neck radiation. Clin Oral Investig. 2012;16(4):1305-12.

https://doi.org/10.1007/s00784-011-0612-1

PMid:21904917

Wilson D, Thewes S, Zakikhany K, Fradin C, Albrecht A, Almeida R, et al. Identifying infection-associated genes of Candida albicans in the postgenomic era. FEMS Yeast Res. 2009;9(5):688-700.

https://doi.org/10.1111/j.1567-1364.2009.00524.x

PMid:19473261

Zida A, Yacouba A, Bamba S, Sangare I, Sawadogo M, Guiguemde T, et al. In vitro susceptibility of Candida albicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso). JMM. 2017;27(4):469-75.

https://doi.org/10.1016/j.mycmed.2017.07.001

PMid:28754462

de Paula SB, Morey AT, Santos JP, dos Santos PM, Gameiro DG, Kerbauy G, et al. Oral Candida colonization in HIV-infected patients in Londrina-PR, Brazil: antifungal susceptibility and virulence factors. JIDC. 2015;9(12):1350-9.

https://doi.org/10.3855/jidc.6970

PMid:26719941

Bulacio L, Paz M, Ramadán S, Ramos L, Pairoba C, Sortino M, et al. Oral infections caused by yeasts in patients with head and neck cancer undergoing radiotherapy, Identification of the yeasts and evaluation of their antifungal susceptibility. Journal de mycologie medicale. 2012;22(4):348-53.

https://doi.org/10.1016/j.mycmed.2012.08.002

PMid:23518170

Kurnatowski P, Moqbil S, Kaczmarczyk D. Signs, symptoms and the prevalence of fungi detected from the oral cavity and pharynx of radiotherapy subjects with head and neck tumors, and their susceptibility to chemotherapeutics. Ann Parasitol. 2014;60(3):207-13.

Burlage FR, Coppes RP, Meertens H, Stokman MA, Vissink A. Parotid and submandibular/sublingual salivary flow during high dose radiotherapy. Radiotherapy and oncology: Radiother Oncol. 2001;61(3):271-4.

https://doi.org/10.1016/S0167-8140(01)00427-3

PMid:11730996

Dambroso D, Svidzinski Tie, Svidzinski Ae, Dalalio M, Machado DO, Moliterno RA. Radiotherapy effect on frequency of Candida spp and on virulence of C albicans isolated from the oral cavity of head and neck cancer patients. Rev Ciênc Farm Básica Apl. 2009;30(2):153-9.

Chou Y-C, Wang Y-K, Charng M-J, Ueng Y-F. Determination of serum atorvastatin concentrations in lipid-controlling patients with and without myalgia syndrome. JFDA. 2013;21(2):147-53.

https://doi.org/10.1016/j.jfda.2013.05.003

Do not use your browser's 'BACK' button.

Downloads

Published

2024-12-30

How to Cite

Golestannejad, Z., Khozeimeh, F., Taheri , S., Feyzi , S., Abbasi , F., Saberi, Z., … Ataie, Z. (2024). Investigating The Antifungal Activity of Atorvastatin Compared with Nystatin on Oral Candidiasis before and during Head and Neck Radiotherapy: Atorvastatin Vs. Nystatin for Oral Candidiasis in Radiotherapy. Galen Medical Journal, 13(SP1), e3717. https://doi.org/10.31661/gmj.v13iSP1.3717

Issue

Vol. 13 No. SP1 (2024): Oral and Maxillofacial Disorders

Section

Original Article

License

Copyright (c) 2024 Galen Medical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

https://creativecommons.org/licenses/by/4.0/